Table of Contents
1 Report Overview
1.1 Research Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Hip Osteoarthritis Pain Drug Market Size Growth Rate by Type
1.3.2 Oral
1.3.3 Injection
1.3.4 External
1.4 Market Segment by Application
1.4.1 Global Hip Osteoarthritis Pain Drug Market Share by Application (2018-2025)
1.4.2 Medical Care
1.4.3 Personal Care
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hip Osteoarthritis Pain Drug Market Size
2.1.1 Global Hip Osteoarthritis Pain Drug Revenue 2013-2025
2.1.2 Global Hip Osteoarthritis Pain Drug Sales 2013-2025
2.2 Hip Osteoarthritis Pain Drug Growth Rate by Regions
2.2.1 Global Hip Osteoarthritis Pain Drug Sales by Regions 2013-2018
2.2.2 Global Hip Osteoarthritis Pain Drug Revenue by Regions 2013-2018
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
3 Market Share by Manufacturers
3.1 Hip Osteoarthritis Pain Drug Sales by Manufacturers
3.1.1 Hip Osteoarthritis Pain Drug Sales by Manufacturers 2013-2018
3.1.2 Hip Osteoarthritis Pain Drug Sales Market Share by Manufacturers 2013-2018
3.2 Revenue by Manufacturers
3.2.1 Hip Osteoarthritis Pain Drug Revenue by Manufacturers (2013-2018)
3.2.2 Hip Osteoarthritis Pain Drug Revenue Share by Manufacturers (2013-2018)
3.2.3 Global Hip Osteoarthritis Pain Drug Market Concentration Ratio (CR5 and HHI)
3.3 Hip Osteoarthritis Pain Drug Price by Manufacturers
3.4 Key Manufacturers Hip Osteoarthritis Pain Drug Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Hip Osteoarthritis Pain Drug Market
3.6 Key Manufacturers Hip Osteoarthritis Pain Drug Product Offered
3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Oral Sales and Revenue (2013-2018)
4.1.2 Injection Sales and Revenue (2013-2018)
4.1.3 External Sales and Revenue (2013-2018)
4.2 Global Hip Osteoarthritis Pain Drug Sales Market Share by Type
4.3 Global Hip Osteoarthritis Pain Drug Revenue Market Share by Type
4.4 Hip Osteoarthritis Pain Drug Price by Type
5 Market Size by Application
5.1 Overview
5.2 Global Hip Osteoarthritis Pain Drug Sales by Application
6 North America
6.1 North America Hip Osteoarthritis Pain Drug Breakdown Data by Company
6.2 North America Hip Osteoarthritis Pain Drug Breakdown Data by Type
6.3 North America Hip Osteoarthritis Pain Drug Breakdown Data by Application
6.4 North America Hip Osteoarthritis Pain Drug Breakdown Data by Countries
6.4.1 North America Hip Osteoarthritis Pain Drug Sales by Countries
6.4.2 North America Hip Osteoarthritis Pain Drug Revenue by Countries
6.4.3 United States
6.4.4 Canada
6.4.5 Mexico
7 Europe
7.1 Europe Hip Osteoarthritis Pain Drug Breakdown Data by Company
7.2 Europe Hip Osteoarthritis Pain Drug Breakdown Data by Type
7.3 Europe Hip Osteoarthritis Pain Drug Breakdown Data by Application
7.4 Europe Hip Osteoarthritis Pain Drug Breakdown Data by Countries
7.4.1 Europe Hip Osteoarthritis Pain Drug Sales by Countries
7.4.2 Europe Hip Osteoarthritis Pain Drug Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 UK
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Hip Osteoarthritis Pain Drug Breakdown Data by Company
8.2 Asia Pacific Hip Osteoarthritis Pain Drug Breakdown Data by Type
8.3 Asia Pacific Hip Osteoarthritis Pain Drug Breakdown Data by Application
8.4 Asia Pacific Hip Osteoarthritis Pain Drug Breakdown Data by Countries
8.4.1 Asia Pacific Hip Osteoarthritis Pain Drug Sales by Countries
8.4.2 Asia Pacific Hip Osteoarthritis Pain Drug Revenue by Countries
8.4.3 China
8.4.4 Japan
8.4.5 Korea
8.4.6 India
8.4.7 Australia
8.4.8 Indonesia
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Thailand
8.4.12 Vietnam
9 Central & South America
9.1 Central & South America Hip Osteoarthritis Pain Drug Breakdown Data by Company
9.2 Central & South America Hip Osteoarthritis Pain Drug Breakdown Data by Type
9.3 Central & South America Hip Osteoarthritis Pain Drug Breakdown Data by Application
9.4 Central & South America Hip Osteoarthritis Pain Drug Breakdown Data by Countries
9.4.1 Central & South America Hip Osteoarthritis Pain Drug Sales by Countries
9.4.2 Central & South America Hip Osteoarthritis Pain Drug Revenue by Countries
9.4.3 Brazil
10 Middle East and Africa
10.1 Middle East and Africa Hip Osteoarthritis Pain Drug Breakdown Data by Type
10.2 Middle East and Africa Hip Osteoarthritis Pain Drug Breakdown Data by Application
10.3 Middle East and Africa Hip Osteoarthritis Pain Drug Breakdown Data by Countries
10.3.1 Middle East and Africa Hip Osteoarthritis Pain Drug Sales by Countries
10.3.2 Middle East and Africa Hip Osteoarthritis Pain Drug Revenue by Countries
10.3.3 GCC Countries
10.3.4 Egypt
10.3.5 South Africa
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Company Description and Business Overview
11.1.3 Sales, Revenue and Market Share of Hip Osteoarthritis Pain Drug
11.1.4 Hip Osteoarthritis Pain Drug Product Introduction
11.1.5 Pfizer Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Company Description and Business Overview
11.2.3 Sales, Revenue and Market Share of Hip Osteoarthritis Pain Drug
11.2.4 Hip Osteoarthritis Pain Drug Product Introduction
11.2.5 Johnson & Johnson Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Details
11.3.2 Company Description and Business Overview
11.3.3 Sales, Revenue and Market Share of Hip Osteoarthritis Pain Drug
11.3.4 Hip Osteoarthritis Pain Drug Product Introduction
11.3.5 GlaxoSmithKline Recent Development
11.4 Bayer
11.4.1 Bayer Company Details
11.4.2 Company Description and Business Overview
11.4.3 Sales, Revenue and Market Share of Hip Osteoarthritis Pain Drug
11.4.4 Hip Osteoarthritis Pain Drug Product Introduction
11.4.5 Bayer Recent Development
11.5 Eli Lilly
11.5.1 Eli Lilly Company Details
11.5.2 Company Description and Business Overview
11.5.3 Sales, Revenue and Market Share of Hip Osteoarthritis Pain Drug
11.5.4 Hip Osteoarthritis Pain Drug Product Introduction
11.5.5 Eli Lilly Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Company Description and Business Overview
11.6.3 Sales, Revenue and Market Share of Hip Osteoarthritis Pain Drug
11.6.4 Hip Osteoarthritis Pain Drug Product Introduction
11.6.5 Novartis Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Details
11.7.2 Company Description and Business Overview
11.7.3 Sales, Revenue and Market Share of Hip Osteoarthritis Pain Drug
11.7.4 Hip Osteoarthritis Pain Drug Product Introduction
11.7.5 Sanofi Recent Development
11.8 Horizon Pharma
11.8.1 Horizon Pharma Company Details
11.8.2 Company Description and Business Overview
11.8.3 Sales, Revenue and Market Share of Hip Osteoarthritis Pain Drug
11.8.4 Hip Osteoarthritis Pain Drug Product Introduction
11.8.5 Horizon Pharma Recent Development
11.9 Abbott
11.9.1 Abbott Company Details
11.9.2 Company Description and Business Overview
11.9.3 Sales, Revenue and Market Share of Hip Osteoarthritis Pain Drug
11.9.4 Hip Osteoarthritis Pain Drug Product Introduction
11.9.5 Abbott Recent Development
11.10 Mylan
11.10.1 Mylan Company Details
11.10.2 Company Description and Business Overview
11.10.3 Sales, Revenue and Market Share of Hip Osteoarthritis Pain Drug
11.10.4 Hip Osteoarthritis Pain Drug Product Introduction
11.10.5 Mylan Recent Development
11.11 Daiichi Sankyo
11.12 TEVA
11.13 Almatica Pharma
11.14 Astellas Pharma
11.15 Tide Pharmaceutical
11.16 Iroko Pharmaceuticals
11.17 Hengrui Pharmaceutical
11.18 Abiogen Pharma
12 Value Chain and Sales Channels Analysis
12.1 Value Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Hip Osteoarthritis Pain Drug Sales Channels
12.2.2 Hip Osteoarthritis Pain Drug Distributors
12.3 Hip Osteoarthritis Pain Drug Customers
13 Market Forecast
13.1 Global Hip Osteoarthritis Pain Drug Sales and Revenue Forecast 2018-2025
13.2 Global Hip Osteoarthritis Pain Drug Sales Forecast by Type
13.3 Global Hip Osteoarthritis Pain Drug Sales Forecast by Application
13.4 Hip Osteoarthritis Pain Drug Forecast by Regions
13.4.1 Global Hip Osteoarthritis Pain Drug Sales Forecast by Regions 2018-2025
13.4.2 Global Hip Osteoarthritis Pain Drug Revenue Forecast by Regions 2018-2025
13.5 North America Market Forecast
13.5.1 North America Hip Osteoarthritis Pain Drug Forecast by Countries 2018-2025
13.5.2 United States
13.5.3 Canada
13.5.4 Mexico
13.6 Europe Market Forecast
13.6.1 Europe Hip Osteoarthritis Pain Drug Forecast by Countries 2018-2025
13.6.2 Germany
13.6.3 France
13.6.4 UK
13.6.5 Italy
13.6.6 Russia
13.7 Asia Pacific Market Forecast
13.7.1 Asia Pacific Hip Osteoarthritis Pain Drug Sales Forecast by Countries 2018-2025
13.7.2 China
13.7.3 Japan
13.7.4 Korea
13.7.5 India
13.7.6 Australia
13.7.7 Indonesia
13.7.8 Thailand
13.7.9 Malaysia
13.7.10 Philippines
13.7.11 Vietnam
13.8 Central & South America Market Forecast
13.8.1 Central & South America Hip Osteoarthritis Pain Drug Sales Forecast by Countries 2018-2025
13.8.2 Brazil
13.9 Middle East and Africa Market Forecast
13.9.1 Middle East and Africa Hip Osteoarthritis Pain Drug Sales Forecast by Countries 2018-2025
13.9.2 GCC Countries
13.9.3 Egypt
13.9.4 South Africa
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
15.2 Author Details
15.3 Disclaimer
【掲載企業】
Pfizer、Johnson & Johnson、GlaxoSmithKline、Bayer、Eli Lilly、Novartis、Sanofi、Horizon Pharma、Abbott、Mylan、Daiichi Sankyo、TEVA、Almatica Pharma、Astellas Pharma、Tide Pharmaceutical、Iroko Pharmaceuticals、Hengrui Pharmaceutical、Abiogen Pharma
【免責事項】
https://www.globalresearch.jp/disclaimer